Literature DB >> 10739777

Calcified subcutaneous arterioles with infarcts of the subcutis and skin ("calciphylaxis") in chronic renal failure.

D T Janigan1, D J Hirsch, G A Klassen, A S MacDonald.   

Abstract

Patients with chronic renal failure (CRF) are at increased risk for pathological calcifications because of increased serum calcium-phosphorus products. A minority, including those undergoing dialysis, develop a syndrome of deep skin ulcerations in association with calcification of subcutaneous arterioles. The body distribution of the skin lesions may be proximal (central), distal (peripheral), or both. Since 1968, this syndrome has been called "calciphylaxis" in the belief that it is the human analogue of Selye's experimental models of tissue calcification. Our review emphasizes that this syndrome comprises two separate processes not found in calciphylaxis: calcification of subcutaneous arterioles and infarctions of subcutaneous adipose tissue (panniculus adiposus) and skin. The infarctions are acute and clinically dramatic, whereas the calcific arteriolopathy is preexistent, having developed slowly, sometimes over years, and silently. Separating these two processes facilitates analyses of pathogenetic factors, such as those that target subcutaneous arterioles for calcification and those that interfere with blood flow through the calcified arterioles, sufficient in some patients to cause the infarctions, and of why obesity in CRF is a syndrome risk factor. This approach further helps to provide a much needed standardized definition of the syndrome, thereby facilitating comparisons of the results of such treatments as parathyroidectomy, anticoagulants, and phosphate binders. Finally, the separation shows why the application of such terms as calciphylaxis and calcifying panniculitis to this syndrome is inappropriate.

Entities:  

Mesh:

Year:  2000        PMID: 10739777     DOI: 10.1016/s0272-6386(00)70003-5

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  26 in total

1.  Calcific uraemic arteriolopathy.

Authors:  Molly B Disbrow; Ibrahim Qaqish; Mark Kransdorf; Harini A Chakkera
Journal:  BMJ Case Rep       Date:  2015-08-27

Review 2.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 3.  Calciphylaxis: diagnosis and clinical features.

Authors:  Matsuhiko Hayashi
Journal:  Clin Exp Nephrol       Date:  2013-02-21       Impact factor: 2.801

4.  Curious case of calciphylaxis leading to acute mitral regurgitation.

Authors:  Grant Gardner Gallimore; Blair Curtis; Andria Smith; Michael Benca
Journal:  BMJ Case Rep       Date:  2014-04-30

Review 5.  Calciphylaxis.

Authors:  R V Mathur; J R Shortland; A M el-Nahas
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

Review 6.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

7.  Penile and generalised calciphylaxis in peritoneal dialysis.

Authors:  Edmond Sarkis
Journal:  BMJ Case Rep       Date:  2015-04-16

8.  Calciphylaxis in chronic renal failure: An approach to risk factors.

Authors:  W Rezaie; H A J M Overtoom; M Flens; R J L Klaassen
Journal:  Indian J Nephrol       Date:  2009-07

9.  Metal deposition in calcific uremic arteriolopathy.

Authors:  Lavanya Amuluru; Whitney High; Kim M Hiatt; James Ranville; Sudhir V Shah; Bilal Malik; Sundararaman Swaminathan
Journal:  J Am Acad Dermatol       Date:  2009-04-29       Impact factor: 11.527

10.  Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy.

Authors:  Peter W Santos; Jianghua He; Ahmad Tuffaha; James B Wetmore
Journal:  Int Urol Nephrol       Date:  2017-10-20       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.